MicroRNAs as Biomarkers for Obstructive Sleep Apnea
University of Pennsylvania
500 participants
Apr 1, 2024
OBSERVATIONAL
Conditions
Summary
Although obstructive sleep apnea (OSA) is a common disorder, there are no blood biomarkers for identification and management of these patients. This project will study microRNAs in order to develop and validate blood biomarkers that are specific to OSA, useful for identification of cases with OSA, reflective of efficacy of therapy, and able to predict blood pressure response to treatment of OSA.
Eligibility
Inclusion Criteria5
- age 18-75 years
- moderate-severe OSA (defined as AHI ≥15 events/hour)
- willing to accept PAP therapy
- age 18-75 years
- no OSA (defined as AHI <5 events/hour)
Exclusion Criteria16
- current use of PAP or other OSA treatments
- home oxygen therapy
- recent changes (within 3 months) to BP medications among those who are on these medications
- presence of Cheyne-Stokes Respiration (CSR) in sleep study
- predominantly central sleep apnea (AHI≥15 events/hour, with >50% central events)
- pregnancy
- clinical history of chronic kidney disease (Stage 5) requiring dialysis, or renal transplant
- organ transplantation
- self-reported sleep duration less than 5 hours per night on weeknights (work nights)
- current night shift work
- home oxygen therapy
- pregnancy
- clinical history of chronic kidney disease (Stage 5) requiring dialysis, or renal transplant
- organ transplantation
- self-reported sleep duration less than 5 hours per night on weeknights (work nights)
- current night shift work
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Case participants will use Positive Airway Pressure (PAP) treatment as part of routine clinical care.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06189755